Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

PURPOSE: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Wang, Hai-ying, Chu, Jun-feng, Zhang, Peng, Wang, Jia-qiang, Yan, Zheng, Yao, Shu-na, Yao, Zhi-hua, Liu, Yan-yan
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038775/
https://ncbi.nlm.nih.gov/pubmed/32110053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S235349
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados